A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective ...

Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in oncology.

But the pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects in some cases. Antibody-drug conjugates ...

Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...